Comparison of Sirolimus and Paclitaxel-Eluting Stents for Complex Coronary Lesions: An Intravascular Ultrasound Study
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Recent intravascular ultrasound (IVUS) studies of sirolimus-eluting stents (SES) and paclitaxeleluting stents (PES) have demonstrated a significant reduction in neointimal hyperplasia (NIH) based on simple coronary lesions. In this study, we evaluated the efficacy of SES and PES using IVUS in complex coronary lesions. Methods: Eighty-seven patients in whom 95 drug-eluting stents (66 SES and 29 PES) were implanted in complex coronary lesions were enrolled in this study. Case selection was based on the availability of IVUS and quantitative coronary angiographic (QCA) examinations at the index procedure and at follow-up. The neointimal volume index (volume/length: NIVI) and percent neointimal volume (% NIV) were calculated. The longitudinal length of stented segments without IVUS-detectable NIH was also evaluated. Results: The baseline patient demographics were similar between the SES and PES groups. At follow-up, no significant differences were observed in the vessel, plaque, or stent volume indices between the two groups. However, the NIVI and % NIV were significantly lower in the SES group (p<0.01). The longitudinal length of stented segments without IVUS-detectable NIH was significantly higher in the SES group (p<0.01). The net gain was significantly larger in the SES group (2.3±0.7 vs. 2.0×0.6 ㎜, p=0.025), while the rate of major adverse cardiac events was similar between the two groups. Conclusions: Although SES showed significantly greater suppression of NIH at follow-up, both stents were highly effective at inhibiting NIH in complex coronary lesions.
Abstract
Background/Aims: Recent intravascular ultrasound (IVUS) studies of sirolimus-eluting stents (SES) and paclitaxeleluting stents (PES) have demonstrated a significant reduction in neointimal hyperplasia (NIH) based on simple coronary lesions. In this study, we evaluated the efficacy of SES and PES using IVUS in complex coronary lesions. Methods: Eighty-seven patients in whom 95 drug-eluting stents (66 SES and 29 PES) were implanted in complex coronary lesions were enrolled in this study. Case selection was based on the availability of IVUS and quantitative coronary angiographic (QCA) examinations at the index procedure and at follow-up. The neointimal volume index (volume/length: NIVI) and percent neointimal volume (% NIV) were calculated. The longitudinal length of stented segments without IVUS-detectable NIH was also evaluated. Results: The baseline patient demographics were similar between the SES and PES groups. At follow-up, no significant differences were observed in the vessel, plaque, or stent volume indices between the two groups. However, the NIVI and % NIV were significantly lower in the SES group (p<0.01). The longitudinal length of stented segments without IVUS-detectable NIH was significantly higher in the SES group (p<0.01). The net gain was significantly larger in the SES group (2.3±0.7 vs. 2.0×0.6 ㎜, p=0.025), while the rate of major adverse cardiac events was similar between the two groups. Conclusions: Although SES showed significantly greater suppression of NIH at follow-up, both stents were highly effective at inhibiting NIH in complex coronary lesions.
참고문헌 (27)
- Morice MC, "A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization", N Engl J Med, 346, pp.1773~1780 (2002)
- Moses JW, "Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery", N Engl J Med, 349, pp.1315~1323 (2003)
- Colombo A, "Randomized study to assess the effectiveness of slow- and moderate-release polymerbased paclitaxel-eluting stents for coronary artery lesions", Circulation, 108, pp.788~794 (2003)
- Stone GW, "A polymer-based, paclitaxeleluting stent in patients with coronary artery disease", N Engl J Med, 350, pp.221~231 (2004)
- Degertekin M, "Evaluation of coronary remodeling after sirolimus-eluting stent implantation by serial three-dimensional intravascular ultrasound", Am J Cardiol, 91, pp.1046~1050 (2003)
- 김성환, "약물방출 스텐트의 최근 동향", 대한내과학회지, 75(4), pp.370~382 (2008), 대한내과학회
- Morino Y, "Delivered dose and vascular response after beta-radiation for in-stent restenosis: retrospective dosimetry and volumetric intravascular ultrasound analysis", Circulation, 106, pp.2334~2339 (2002)
- Honda Y, "Novel drug-delivery stent: intravascular ultrasound observations from the first human experience with the QP2- eluting polymer stent system", Circulation, 104, pp.380~383 (2001)
- Kobayashi Y, "Long-term vessel response to a self-expanding coronary stent: a serial volumetric intravascular ultrasound analysis from the ASSURE trial", J Am Coll Cardiol, 37, pp.1329~1334 (2001)
- Ako J, "Late incomplete stent apposition after sirolimus-eluting stent implantation: a serial intravascular \ultrasound analysis", J Am Coll Cardiol, 46, pp.1002~1005 (2005)
- Dawkins KD, "Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice", Circulation, 112, pp.3306~3313 (2005)
- Chen JL, "Comparison of short- and midterm outcomes between CYPHER and TAXUS stents in patients with complex lesions of the coronary arteries", Chin Med J, 119, pp.21~25 (2006)
- Kumar S, "Outcome in the realworld of coronary high-risk intervention with drug-eluting stents (ORCHID) -a single-center study comparing Cypher sirolimuseluting with Taxus paclitaxel-eluting stents", Catheter Cardiovasc Interv, 68, pp.663~668 (2006)
- Grube E, "TAXUS VI 2-year followup: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions", Eur Heart J, 28, pp.2578~2582 (2007)
- Urban P, "Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year followup of the e-Cypher registry", Circulation, 113, pp.1434~1441 (2006)
- Galløe AM, "Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial", JAMA, 299, pp.409~416 (2008)
- Roy P, "Comparison between sirolimusand paclitaxel-eluting stents in complex patient and lesions subsets", Catheter Cardiovasc Interv, 70, pp.167~172 (2007)
- Morice MC, "Sirolimus- vs paclitaxeleluting stents in de novo coronary artery lesions. The REALITY trial: a randomized controlled trial", JAMA, 295, pp.904~ (2006)
- Windecker S, "Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization", N Engl J Med, 353, pp.653~662 (2005)
- Dibra A, "Paclitaxel-eluting or sirolimuseluting stents to prevent restenosis in diabetic patients", N Engl J Med, 353, pp.663~670 (2005)
- Cervinka P, "Head-to-head comparison between sirolimus-eluting and paclitaxel-eluting stents in patients with complex coronary artery disease: an intravascular ultrasound study", Catheter Cardiovasc Interv, 67, pp.846~851 (2006)
- Petronio AS, "Randomized comparison of sirolimus and paclitaxel drug-eluting stents for long lesions in the left anterior descending artery: an intravascular ultrasound study", J Am Coll Cardiol, 49, pp.539~546 (2007)
- Colombo A, "Preliminary observations regarding angiographic pattern of restenosis after rapamycineluting stent implantation", Circulation, 107, pp.2178~2180 (2003)
- Iakovou I, "Angiographic patterns of restenosis after paclitaxel-eluting stent implantation", J Am Coll Cardiol, 45, pp.805~806 (2005)
- Kimura M, "Outcome after acute incomplete sirolimus-eluting stent apposition as assessed by serial intravascular ultrasound", Am J Cardiol, 98, pp.436~442 (2006)
- Takeuchi H, "Frequency and characteristics of incomplete stent apposition during and after\ sirolimus-eluting stent implantation", J Cardiol, 50, pp.111~118 (2007)
- Hong MK, "Late stent malapposition after drug-eluting stent implantation: an intravascular ultrasound analysis with long-term follow-up", Circulation, 113, pp.414~419 (2006)